A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

ATRIPLA is licensed for use only in HIV-positive persons whose viral loads

Saved in:
Bibliographic Details
Published in:Infection 2014-08, Vol.42 (4), p.757-762
Main Authors: Mocroft, A., Reiss, P., Rakhmanova, A., Banhegyi, D., Phillips, A. N., De Wit, S., Ristola, M., Lundgren, J. D., Grarup, J., Kirk, O.
Format: Article
Language:English
Subjects:
Adenine - analogs & derivatives
Adenine - therapeutic use
Adult
Anti-HIV Agents - therapeutic use
Antiretroviral agents
Brief Report
Cohort Studies
Data Collection
Deoxycytidine - analogs & derivatives
Deoxycytidine - therapeutic use
Drug Combinations
Drug Utilization
Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Europe
Family Medicine
Female
General Practice
HIV Infections - drug therapy
Human immunodeficiency virus
Humans
Infectious Diseases
Internal Medicine
Male
Medicine
Medicine & Public Health
Organophosphonates - therapeutic use
Oxazines - therapeutic use
Polls & surveys
Prospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ATRIPLA is licensed for use only in HIV-positive persons whose viral loads
ISSN:0300-8126
1439-0973
DOI:10.1007/s15010-014-0630-4